Aprinocarsen

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameAprinocarsen
Drug Alias NameAffinitakAprenocarsen sodiumAffinitacISIS-3521CGP-64128A +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionProtein kinase C alpha inhibitors
TargetsProtein kinase C alpha
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSweden +[21] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIonis Pharmaceuticals IncEli Lilly And CompanyNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A